165 related articles for article (PubMed ID: 35600575)
1. Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.
van Ruiten CC; Veltman DJ; Nieuwdorp M; IJzerman RG
Front Endocrinol (Lausanne); 2022; 13():863592. PubMed ID: 35600575
[TBL] [Abstract][Full Text] [Related]
2. Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
van Ruiten CC; Veltman DJ; Schrantee A; van Bloemendaal L; Barkhof F; Kramer MHH; Nieuwdorp M; IJzerman RG
J Clin Endocrinol Metab; 2022 May; 107(6):e2590-e2599. PubMed ID: 35134184
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
van Ruiten CC; Veltman DJ; Wijdeveld M; Ten Kulve JS; Kramer MHH; Nieuwdorp M; IJzerman RG
Diabetes Obes Metab; 2022 Aug; 24(8):1588-1597. PubMed ID: 35491524
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
van Ruiten CC; Smits MM; Kok MD; Serné EH; van Raalte DH; Kramer MHH; Nieuwdorp M; IJzerman RG
Cardiovasc Diabetol; 2022 Apr; 21(1):63. PubMed ID: 35484607
[TBL] [Abstract][Full Text] [Related]
5. A
Brown E; Wilton MM; Sprung VS; Harrold JA; Halford JCG; Stancak A; Burgess M; Howarth E; Umpleby AM; Kemp GJ; Wilding JP; Cuthbertson DJ
BMJ Open; 2021 Jul; 11(7):e045663. PubMed ID: 34285005
[TBL] [Abstract][Full Text] [Related]
6. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
7. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
van Ruiten CC; van der Aart-van der Beek AB; IJzerman RG; Nieuwdorp M; Hoogenberg K; van Raalte DH; Heerspink HJL
Diabetes Obes Metab; 2021 Aug; 23(8):1851-1858. PubMed ID: 33908691
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.
van Bloemendaal L; IJzerman RG; Ten Kulve JS; Barkhof F; Konrad RJ; Drent ML; Veltman DJ; Diamant M
Diabetes; 2014 Dec; 63(12):4186-96. PubMed ID: 25071023
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?
Hummel J; Kullmann S; Heni M
J Clin Endocrinol Metab; 2022 Jun; 107(7):e3080-e3081. PubMed ID: 35323940
[No Abstract] [Full Text] [Related]
10. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
Rajeev SP; Sprung VS; Roberts C; Harrold JA; Halford JC; Stancak A; Boyland EJ; Kemp GJ; Cuthbertson DJ; Wilding JP
BMJ Open; 2017 Jan; 7(1):e013539. PubMed ID: 28132008
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Lundkvist P; Sjöström CD; Amini S; Pereira MJ; Johnsson E; Eriksson JW
Diabetes Obes Metab; 2017 Jan; 19(1):49-60. PubMed ID: 27550386
[TBL] [Abstract][Full Text] [Related]
12. No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE).
Rajeev SP; Roberts CA; Brown E; Sprung VS; Harrold JA; Halford JCG; Stancak A; Boyland EJ; Kemp GJ; Perry J; Howarth E; Jackson R; Wiemken A; Schwab R; Cuthbertson DJ; Wilding JPH
Diabetes Obes Metab; 2023 Dec; 25(12):3621-3631. PubMed ID: 37667658
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J
Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478
[TBL] [Abstract][Full Text] [Related]
15. Does Dapagliflozin Affect Energy Intake and Appetite? A Randomized, Controlled Exploratory Study in Healthy Subjects.
Bertran E; Berlie HD; Nixon A; Jaber L
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):119-125. PubMed ID: 29723443
[TBL] [Abstract][Full Text] [Related]
16. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial.
Veelen A; Andriessen C; Op den Kamp Y; Erazo-Tapia E; de Ligt M; Mevenkamp J; Jörgensen JA; Moonen-Kornips E; Schaart G; Esterline R; Havekes B; Oscarsson J; Schrauwen-Hinderling VB; Phielix E; Schrauwen P
Metabolism; 2023 Mar; 140():155396. PubMed ID: 36592688
[TBL] [Abstract][Full Text] [Related]
17. Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
Ferrannini E; Baldi S; Frías JP; Guja C; Hardy E; Repetto E; Jabbour SA; DeFronzo RA
Diabetes Obes Metab; 2020 Jan; 22(1):99-106. PubMed ID: 31469220
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.
Bae JH; Choi HJ; Cho KIK; Kim LK; Kwon JS; Cho YM
Diabetes Metab J; 2020 Apr; 44(2):248-259. PubMed ID: 31701698
[TBL] [Abstract][Full Text] [Related]
19. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
[TBL] [Abstract][Full Text] [Related]
20. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial.
van Ruiten CC; Ten Kulve JS; van Bloemendaal L; Nieuwdorp M; Veltman DJ; IJzerman RG
Psychoneuroendocrinology; 2022 Mar; 137():105667. PubMed ID: 35033928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
